



Clearbridge continues collaboration with Olivia Newton-John Cancer Research Institute

SINGAPORE – 27 April 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited with a focus on the delivery of precision medicine in Asia, is pleased to announce its continued collaboration with the Olivia Newton-John Cancer Research Institute (“ONJCRI”) for Epidermal Growth Factor Receptor gene (EGFR) mutation analysis testing services on plasma DNA from patient blood specimens.

The move is part of the Group’s strategy to augment its offerings within its laboratory testing services through collaborations with third party clinical and technology partners.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, “We have been working closely with ONJCRI since 2016 and we are happy to continue our collaboration with them. Through third party collaborations, Clearbridge is able to reap synergies that ultimately benefit patients. They include the enhancement of the range of products and services we offer and access to cutting edge research and development activities. As always, our aim is to empower healthcare professionals to make more reliable and accurate diagnoses that provide better insights into disease management, and we believe such collaborations will bring us closer to this goal.”

###

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, ownership and operation of medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. For more information, please visit us at www.clearbridgehealth.com.

Issued by and on behalf of Clearbridge Health Limited

August Consulting

Tel: +65 6733 8873

Silvia Heng, silviaheng@august.com.sg

Wrisney Tan, wrisneytan@august.com.sg

Zavier Ong, zavierong@august.com.sg



*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**").*

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.